摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+)-9a-epi-stemoamide | 1191043-74-9

中文名称
——
中文别名
——
英文名称
(+)-9a-epi-stemoamide
英文别名
(1R,2R,3S,6R)-3-methyl-5-oxa-10-azatricyclo[8.3.0.02,6]tridecane-4,11-dione
(+)-9a-epi-stemoamide化学式
CAS
1191043-74-9
化学式
C12H17NO3
mdl
——
分子量
223.272
InChiKey
MIHPYTYSLJCWQU-YSSBGUOXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (3aR,10aR,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione碘甲烷lithium hexamethyldisilazane 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以60%的产率得到(+)-9a-epi-stemoamide
    参考文献:
    名称:
    Synthesis of (+)-9a-epi-Stemoamide via DBU-Catalyzed Michael Addition of Nitroalkane
    摘要:
    我们描述了 (+)-9a-epi-stemoamide 的实际合成,该合成是通过 α,β-不饱和 γ-丁内酯通过六个步骤实现的。当前方法的主要特点包括 DBU 催化的硝基烷的迈克尔加成反应和硝基酯的还原内酰胺化反应。
    DOI:
    10.1055/s-0029-1217558
点击查看最新优质反应信息

文献信息

  • Tailored Synthesis of Skeletally Diverse <i>Stemona</i> Alkaloids through Chemoselective Dyotropic Rearrangements of β‐Lactones
    作者:Zhen Guo、Ruiyang Bao、Yuanhe Li、Yunshan Li、Jingyang Zhang、Yefeng Tang
    DOI:10.1002/anie.202102614
    日期:2021.6.21
    chemoselective dyotropic rearrangements of β-lactones involving alkyl, hydrogen, and aryl migration, respectively. By the rational manipulation of substrate structures and reaction conditions, these dyotropic rearrangements proceeded with excellent efficiency, good chemoselectivity and high stereospecificity. Furthermore, several polycyclic Stemona alkaloids, including saxorumamide, isosaxorumamide, stemonine
    描述了以 β-内酯的定制dyotropic 重排为关键元素的具有骨骼多样性的百部生物碱的集体合成。具体而言,首先通过分别涉及烷基、氢和芳基迁移的 β-内酯的化学选择性dyotropic 重排,获得了与茎酰胺、晚节油环素和帕维司汀相关的三个典型的 5/7/5 三环骨架。通过对底物结构和反应条件的合理控制,这些自致变重排以优异的效率、良好的化学选择性和高立体定向性进行。此外,几种多环百合通过后期衍生化从上述三环骨架中获得生物碱,包括saxorumamide、isosaxorumamide、stemonine和bisdehydroonestemoninine。还开发了一种新型可见光光氧化还原催化的正式 [3+2] 环加成,它为获取氧杂螺丁烯内酯和相关支架提供了宝贵的工具。
  • Computer-aided key step generation in alkaloid total synthesis
    作者:Yingfu Lin、Rui Zhang、Di Wang、Tim Cernak
    DOI:10.1126/science.ade8459
    日期:2023.2.3
    computer-aided synthesis planning with molecular graph editing to minimize the number of synthetic steps required to produce alkaloids. Our study culminated in an enantioselective three-step synthesis of (–)-stemoamide by leveraging high-impact key steps, which could be identified in computer-generated retrosynthesis plans using graph edit distances.
    高效的化学合成对于满足未来对药物、材料和农用化学品的需求至关重要。几十年来,适度复杂分子的逆合成分析已实现自动化,但直到最近,路线可能性的组合爆炸才对计算机硬件和软件提出挑战。在这里,我们探索了一种计算策略,将计算机辅助合成计划与分子图编辑相结合,以最大限度地减少生产生物碱所需的合成步骤数。我们的研究最终实现了 (–)-stemoamide 的对映选择性三步合成,利用高影响关键步骤,这可以在使用图形编辑距离的计算机生成的逆合成计划中识别。
查看更多

同类化合物

金刚大碱 百部碱 新对叶百部碱 对叶百部碱 (7aR,8R,8aS,11S,11aS,11bR,11cR)-8-乙基十二氢-11-甲基-呋喃并[2,3-h]吡咯并[3,2,1-jk][1]苯并氮杂卓-10(2H)-酮 <3'S-<3'α,9'α(S*),9'aα>>-1',2',3',5',6',7',8'-octahydro-4-methyl-5-oxospiropyrrolo<1,2-a>azepin>-3'-carboxylic acid, hydrobromide salt <3'S-<3'α(S*),9'α(S*),9'aα>>-3'-(2,5-dihydro-4-methyl-5-oxo-2-furanyl)-1',2',3',5',6',7',8'-octahydro-4-methylspiropyrrolo<1,2-a>azepin>-5-one stemoamide (2S,4R,3'S,8'R,9a'S,2’’S,4’’S)-8'-methoxy-4-methyl-3’-(4-methyl-5-oxotetrahydrofuran-2-yl)octahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5(4H)-one tuberostemospiroline 2-oxostenine (3aR,10aR,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (3aR,9aS,9bR)-3a,6,8,9,9a,9b-Hexahydro-1H-3-oxa-6a-aza-cyclopenta[e]azulene-2,7-dione (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-1',2',3',7',8',9a'-hexahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(6'H)-dione diethyl (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-5,5'-dioxo-1',2',3',5',6',7,'8',9a'-octahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin-4-yl}phosphonate (2S,4R,3'S,8'R,9a'S,2’’S)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2S,4R,3'S,8'R,9a'S,2’’R)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (1R,2S,10R,12R,16R)-14,14-dimethyl-11,13,15-trioxa-6-azatetracyclo[8.6.0.02,6.012,16]hexadec-8-en-5-one 13-desmethyl-5-oxostenine (3aR,10aS)-1-methyl-3a,4,5,6,10,10a-hexahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(9H)-dione (1R,9R,10R,11S,14S,15S,16R)-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecane-5,13-dione 8-des-ethyl-(8S)-allyl-(-)-tuberostemonine didehydrotuberostemonine (-)-4-thiostenine (-)-4-oxostenine (3aR,10aS,10bS)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (+)-9a-epi-stemoamide (2S,4R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylhexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione isoprotostemonine (1S,2S,3R,4R,6R)-3-hydroxy-4-methoxy-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-11-one (1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one 4-methoxy-3-methyl-5-[(2Z,3aR)-1t-methyl-8t-((2S)-4c-methyl-5-oxo-tetrahydrofuran-2r-yl)-(3ar,10at,10bt)-decahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepin-2-ylidene]-5H-furan-2-one 8-epi-stemoamide sessilifoliamide A (2R,3'S,8'R,9a'S)-3'-(tert-butyldiphenylsilyloxy)methyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-5,5'-dioxo-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-(4H,6'H)-carbaldehyde (2R,3'S,8'R,9a'S,2''R)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione protostemonine (3S,9R,10R,11S,15R)-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadec-6-en-13-one Tuberostemonin (1R,4S,10R,11R,12R,15S,16S)-11-ethyl-15-hydroxy-15-methyl-4-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-13-oxa-5-azatetracyclo[8.6.0.01,5.012,16]hexadecan-14-one (1R,3S,9R,10R,11S,14S,15S,16R)-3-[(2S)-4,4-dimethyl-5-oxooxolan-2-yl]-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (3S,9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-3-[(2S,4R)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (1S,2R,3S)-3-methyl-11-[(2S)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-4-one (9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (10S,11S,14R,15R)-10-ethyl-14-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadeca-1(16),2-dien-13-one